Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms

American Journal of Surgical Pathology

Volumn 38, Issue 5, 2014, Pages 583-592

  Davison, Jon M ^a   Hartman, Douglas A ^a   Singhi, Aatur D ^a   Choudry, Haroon A ^b   Ahrendt, Steven A ^b   Zureikat, Amer H ^b   Ramalingam, Lekshmi ^b   Nikiforova, Marina ^a   Pai, Reetesh K ^a  

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

appendix; disseminated peritoneal adenomucinosis; lowgrade mucinous neoplasm; mucinous adenocarcinoma; peritoneal mucinous carcinomatosis; pseudomyxoma peritonei; SMAD4

Indexed keywords

SMAD4 PROTEIN; SMAD4 PROTEIN, HUMAN; TUMOR MARKER;

APPENDIX TUMOR; ARTICLE; BIOSYNTHESIS; CANCER GRADING; CHROMOSOME 18; COLLOID CARCINOMA; GENETICS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA, MUCINOUS; APPENDICEAL NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 18; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84899481591     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000194     Document Type: Article

References (43)

1. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Genetic analysisof synchronous mucinous tumors of the ovary and appendix. HumPathol. 1996;27:165-171. (Pubitemid 26049470)
2. Ronnett BM, Shmookler BM, Diener-West M, et al. Immunohistochemicalevidence supporting the appendiceal origin of pseudomyxomaperitonei in women. Int J Gynecol Pathol. 1997;16:1-9. (Pubitemid 27199578)
3. Teixeira MR, Qvist H, Giercksky KE, et al. Cytogenetic analysis ofseveral pseudomyxoma peritonei lesions originating from a mucinouscystadenoma of the appendix. Cancer Genet Cytogenet.1997;93:157-159. (Pubitemid 27138662)
4. Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidencesupporting the clonality and appendiceal origin of Pseudomyxomaperitonei in women. Am J Pathol. 1999;154:1849-1855. (Pubitemid 29262868)
5. Young RH, Gilks CB, Scully RE. Mucinous tumors of the appendixassociated with mucinous tumors of the ovary and pseudomyxomaperitonei. A clinicopathological analysis of 22 cases supporting anorigin in the appendix. Am J Surg Pathol. 1991;15:415-429.
6. Carr NJ, Finch J, Ilesley IC, et al. Pathology and prognosis inpseudomyxoma peritonei: a review of 274 cases. J Clin Pathol.2012;65:919-923.
7. Bradley RF, JHt Stewart, Russell GB, et al. Pseudomyxomaperitonei of appendiceal origin: a clinicopathologic analysis of 101patients uniformly treated at a single institution, with literaturereview. Am J Surg Pathol. 2006;30:551-559. (Pubitemid 44265007)
8. Pai RK, Beck AH, Norton JA, et al. Appendiceal mucinousneoplasms: clinicopathologic study of 116 cases with analysis offactors predicting recurrence. Am J Surg Pathol. 2009;33:1425-1439.
9. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendicealmucinous neoplasms: a clinicopathologic analysis of 107 cases. Am JSurg Pathol. 2003;27:1089-1103. (Pubitemid 36909530)
10. Ronnett BM, Yan H, Kurman RJ, et al. Patients with pseudomyxomaperitonei associated with disseminated peritoneal adenomucinosishave a significantly more favorable prognosis than patientswith peritoneal mucinous carcinomatosis. Cancer. 2001;92:85-91. (Pubitemid 32623044)
11. Ronnett BM, Zahn CM, Kurman RJ, et al. Disseminated peritonealadenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologicanalysis of 109 cases with emphasis on distinguishingpathologic features, site of origin, prognosis, and relationship to"pseudomyxoma peritonei". Am J Surg Pathol. 1995;19:1390-1408.
12. Chua TC, Moran BJ, Sugarbaker PH, et al. Early-and long-termoutcome data of patients with pseudomyxoma peritonei fromappendiceal origin treated by a strategy of cytoreductive surgeryand hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-2456.
13. Yan TD, Black D, Savady R, et al. A systematic review on theefficacy of cytoreductive surgery and perioperative intraperitonealchemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484-492. (Pubitemid 46175292)
14. Bryant J, Clegg AJ, Sidhu MK, et al. Systematic review of theSugarbaker procedure for pseudomyxoma peritonei. Br J Surg.2005;92:153-158. (Pubitemid 40269327)
15. McBride K, McFadden D, Osler T. Improved survival of patientswith pseudomyxoma peritonei receiving intraperitoneal chemotherapywith cytoreductive surgery: a systematic review and metaanalysis.J Surg Res. 2013;183:246-252.
16. Cole KL, Choudry HA, Jones HL, et al. Critical role ofhyperthermic intraperitoneal chemoperfusion in the treatment of apatient with Pseudomyxoma peritonei. J Surg Oncol. 2012;106:513-516.
17. Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a Frenchmulticentric study of 301 patients treated with cytoreductive surgeryand intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36:456-462.
18. Shapiro JF, Chase JL, Wolff RA, et al. Modern systemic chemotherapyin surgically unresectable neoplasms of appendiceal origin: asingle-institution experience. Cancer. 2010;116:316-322.
19. Baratti D, Kusamura S, Nonaka D, et al. Pseudomyxoma peritonei:clinical pathological and biological prognostic factors in patientstreated with cytoreductive surgery and hyperthermic intraperitonealchemotherapy (HIPEC). Ann Surg Oncol. 2008;15:526-534.
20. Bijelic L, Kumar AS, Stuart OA, et al. Systemic chemotherapy priorto cytoreductive surgery and HIPEC for carcinomatosis fromappendix cancer: impact on perioperative outcomes and short-termsurvival. Gastroenterol Res Pract. 2012;2012:163284.
21. Sugarbaker PH, Bijelic L, Chang D, et al. Neoadjuvant FOLFOXchemotherapy in 34 consecutive patients with mucinous peritonealcarcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:576-581.
22. Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: BosmanFT, Carneiro CF, Hruban RH, Theise ND, eds. WHO Classificationof Tumours of the Digestive System. Lyon, France: IARC Press;2010:122-125.
23. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer StagingManual. 7th ed. Chicago, IL: Springer; 2010:133-141.
24. Massague J. TGFbeta in Cancer. Cell. 2008;134:215-230.
25. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in humancancer. Biochem Biophys Res Commun. 2003;306:799-804. (Pubitemid 36776201)
26. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemicallabeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas:a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37-43. (Pubitemid 30644436)
27. Jones S, Chen WD, Parmigiani G, et al. Comparative lesionsequencing provides insights into tumor evolution. Proc Natl AcadSci USA. 2008;105:4283-4288. (Pubitemid 351754372)
28. Miyaki M, Iijima T, Konishi M, et al. Higher frequency of Smad4gene mutation in human colorectal cancer with distant metastasis.Oncogene. 1999;18:3098-3103. (Pubitemid 29261230)
29. Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al. Dpc4 proteinin mucinous cystic neoplasms of the pancreas: frequent loss ofexpression in invasive carcinomas suggests a role in geneticprogression. Am J Surg Pathol. 2000;24:1544-1548.
30. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss ofexpression of Dpc4 in pancreatic intraepithelial neoplasia: evidencethat DPC4 inactivation occurs late in neoplastic progression. CancerRes. 2000;60:2002-2006. (Pubitemid 30207663)
31. Maru D, Wu TT, Canada A, et al. Loss of chromosome 18q andDPC4 (Smad4) mutations in appendiceal adenocarcinomas. Oncogene.2004;23:859-864. (Pubitemid 38241288)
32. Maheshwari V, Tsung A, Lin Y, et al. Analysis of loss ofheterozygosity for tumor-suppressor genes can accurately classifyand predict the clinical behavior of mucinous tumors arising fromthe appendix. Ann Surg Oncol. 2006;13:1610-1616. (Pubitemid 44951469)
33. Davison JM, Choudry HA, Pingpank JF, et al. Clinicopathologicand molecular analysis of disseminated appendiceal mucinousneoplasms: Identification of factors predicting survival and proposedcriteria for a three-tiered assessment of tumor grade. ModPathol. 2014. (Accepted for publication).
34. Winter JM, Maitra A, Yeo CJ. Genetics and pathology ofpancreatic cancer. HPB (Oxford). 2006;8:324-336.
35. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumorsuppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
36. Hilgers W, Su GH, Groot Koerkamp B, et al. Novel homozygousdeletions of chromosomal band 18q22 in pancreatic adenocarcinomaidentified by STS marker scanning. Genes Chromosomes Cancer.1999;25:370-375. (Pubitemid 29326144)
37. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 genemutations are associated with poor prognosis in pancreatic cancer.Clin Cancer Res. 2009;15:4674-4679.
38. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression andoutcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002;20:4531-4542. (Pubitemid 35402956)
39. Winter JM, Tang LH, Klimstra DS, et al. Failure patterns inresected pancreas adenocarcinoma: lack of predicted benefit toSMAD4 expression. Ann Surg. 2013;258:331-335.
40. Fleming NI, Jorissen RN, Mouradov D, et al. SMAD2, SMAD3and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73:725-735.
41. Royce SG, Alsop K, Haydon A, et al. The role of SMAD4 in earlyonsetcolorectal cancer. Colorectal Dis. 2010;12:213-219.
42. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation ofcandidate tumour suppressor genes on chromosome 18 in colorectalcancers. Nat Genet. 1996;13:343-346. (Pubitemid 26230501)
43. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in varioustumor types. Cancer Res. 1996;56:2527-2530.